Lipocine (NASDAQ:LPCN)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Friday. They presently have a $10.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 180.11% from the stock’s current price.
Other equities research analysts also recently issued research reports about the company. Roth Capital set a $38.00 price target on Lipocine and gave the company a “buy” rating in a report on Thursday, August 10th. ValuEngine downgraded Lipocine from a “hold” rating to a “sell” rating in a report on Thursday, August 10th.
Shares of Lipocine (LPCN) opened at $3.57 on Friday. Lipocine has a twelve month low of $3.25 and a twelve month high of $5.33.
TRADEMARK VIOLATION WARNING: “Lipocine (LPCN) Stock Rating Reaffirmed by HC Wainwright” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://weekherald.com/2017/12/10/lipocine-lpcn-stock-rating-reaffirmed-by-hc-wainwright.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc and related companies with MarketBeat.com's FREE daily email newsletter.